MORE►
biotechnology
National Center for Therapeutics Manufacturing team members Logan Ardrey, Dr. Arum Han, Dr. Baley Reeves, and Dr. Andrew Syvyk [Photo: NCTM]
UT Arlington and Texas A&M to Launch Biomanufacturing Hub at Dallas’ Pegasus Park
by Quincy Preston | Feb 20, 2025
The new center at Bridge Labs will train the workforce powering North Texas’ biotech boom—helping startups speed therapies, vaccines, and breakthrough biologics from lab bench to patients. Funded in part by Lyda Hill Philanthropies, the National Center for Therapeutics Manufacturing Satellite Campus is set to open this summer.
by Lance Murray |
Dec 9, 2024
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
MORE►
by Quincy Preston |
Aug 9, 2024
With a new CEO and three seasoned industry veterans joining its board, Research Bridge Partners is focused on moving university innovations from the lab to the marketplace.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
MORE►
by Nicole Ward, DRC Data Journalist |
Aug 1, 2024
OncoNano's innovative approach to cancer treatment leverages nanotechnology to bring tumors into the light.
MORE►
The city of Fort Worth and Tarrant County are collaborating with the Texas A&M System on the building of two other buildings for the urban research campus, to be located on four downtown Fort Worth blocks owned by the A&M System.
Texas A&M System Approves New Tarleton State Biotech Institute in Downtown Fort Worth
by Quincy Preston | Sep 1, 2023
Tarleton State University received the go-ahead for a new biotechnology institute as part of Texas A&M-Fort Worth’s burgeoning downtown research campus.
Approved in mid-August by the Texas A&M University System Board of Regents, the biotech institute is situated in one of the nation’s fastest-growing life sciences hubs.
“More than 5,000 biotechnology manufacturing and research and development firms — think Novartis, Alcon, AstraZeneca — call Texas home,” according to the university....
MORE►
by Lance Murray |
Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
by Lance Murray |
Jun 14, 2023
The alliance's first event will be held June 22 in a bid to champion a next-generation, industry-led workforce partnership for North Texas. The alliance seeks to bring together industry trade and manufacturing ecosystems, the organizations said—and it will be working with Dallas College and other partner institutions to help make it happen.
MORE►
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-940x436.jpg)
R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]
Taysha Gene Therapies Lands $50M Investment from Japanese Firm to Fight Rare Diseases
by Kevin Cummings | Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Quincy Preston |
Oct 8, 2020
This year's Nobel Prize in Chemistry, awarded to two female scientists for the development of CRISPR as a gene-editing tool, is a revolution, according to a pair of UTSW scientists.
UTSW's Eric Olson and Rhonda Bassel-Duby use the technology in their work to treat Duchenne muscular dystrophy. Olson also is the co-founder of biotech Exonics Therapeutics, which exited last year in a deal roughly valued at $1B.
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-940x436.jpg)
[Illustration: bestbrk/istockphoto]
Bio North Texas Shifts iC3 Life Sciences Summit to Virtual Event
by Quincy Preston | Sep 22, 2020
Networking—always a highlight of the biotech event— is still a cornerstone thanks to a new virtual conference platform, its organizers said.
MORE►
by Alex Edwards |
Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
by Quincy Preston |
Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
by Quincy Preston |
Aug 20, 2020
OncoNano Medicine, a spinout of University of Texas Southwestern, uses pH as a biomarker to detect metastatic cancer. Its technology, which visualizes a tumor, could be a gamechanger.
MORE►
